CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared to a placebo, drugmakers Biogen and Eisai said on Tuesday. The drug, tested in a global Phase 3 clinical trial, also met all secondary endpoints, showing “target engagement” with reduced levels of amyloid – a …
An experimental drug for Alzheimer’s disease slowed cognitive and functional decline by 27% in a closely monitored clinical trial, the drug’s sponsors said on Tuesday, boosting the therapy’s chances of approval earlier this year. next. Japanese drugmaker Eisai and its US partner, Biogen, said in a press release that the slowing of deterioration, compared to …
Experimental Alzheimer’s drug slows cognitive decline in trial, companies say Read More »
CNN — New cases of monkeypox in the United States have steadily declined in recent weeks, with cases reported in the first week of September reduced to about half of what they were at their peak a month ago. . But the recent death of a Los Angeles County resident — the first attributed to …
